Abstract:For the immune system to function properly, the activation of leukocytes must be tightly regulated. Failures of immune control mechanisms underlie the aberrant targeting of self‐antigens (i.e. autoimmunity) and the collateral damage of healthy tissues during excessive responses to infectious threats or the unnecessary immune mobilization against innocuous commensal microbes. Foxp3‐expressing CD4+ Regulatory T cells (Tregs) are a major cellular force working to prevent these pathologies of immune dysregulation. These cells characteristically exhibit multiple suppressive function that is absolutely required for the maintenance of immune homeostasis. However, these cells can hamper desirable anti‐tumor immune responses in cancer patients. Accordingly, a relative abundance of Tregs in the tumor microenvironment (TME) is a negative prognostic factor in many cancers. Treg‐depleting or antagonizing strategies show promise as potential interventions capable of unleashing anti‐tumor immunity from suppression. The characteristic gene expression and suppressive function of Tregs depend considerably on the stable expression and activity of the transcription factor FOXP3. While transcriptional regulation of the Foxp3gene has been studied in depth, both the expression and function of this factor are also modulated at the protein level. However, the molecular players involved in posttranslational FOXP3 regulation are just beginning to be elucidated. We have found that in the absence of the E3 ligase TRAF6 Tregs were dysfunctional in vivo. In these studies, mice with Treg‐restricted deletion of TRAF6 were highly resistant to implanted tumors and displayed enhanced anti‐tumor immunity. We further determined that FOXP3 undergoes lysine‐63 linked (K63) ubiquitination at lysine 262, and this posttranslational modification was mediated by TRAF6. When deprived of TRAF6 activity or rendered insensitive to K63 ubiquitination, FOXP3 displayed aberrant, perinuclear accumulation and disrupted regulatory function. Thus, K63 ubiquitination by TRAF6 ensures proper localization of FOXP3 and facilitates the transcription factor's gene‐regulating activity in Tregs. These results implicate TRAF6 as a key, hitherto unappreciated posttranslational facilitator of FOXP3 stabilization and Treg suppressive function that may be targeted by novel tolerance‐breaking immunotherapies to improve anti‐tumor immunity and combat disease progression in cancer patients.This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.

TRAF3/STAT6 axis regulates macrophage polarization and tumor progression

TRAF6 promotes IL-4-induced M2 macrophage activation by stabilizing STAT6

TRAF3 regulates the effector function of regulatory T cells and humoral immune responses.

TRAF6 Regulates the Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Tumor-Bearing Host

Modulation of M2 Macrophage Polarization by the Crosstalk Between Stat6 and Trim24

The E3 Ligase TRAF6 Directs FOXP3 Localization and Facilitates Treg Function Through K63‐type Ubiquitination

The Ubiquitin Ligase Traf6 Negatively Regulates The Jak-Stat Signaling Pathway By Binding To Stat3 And Mediating Its Ubiquitination

TRAF3 regulates STAT6 activation and T helper cell differentiation by modulating the phosphatase PTP1B

Advances in the role of STAT3 in macrophage polarization

TRAF6 directs FOXP3 localization and facilitates regulatory T-cell function through K63-linked ubiquitination.

Tim-3 promotes tumor-promoting M2 macrophage polarization by binding to STAT1 and suppressing the STAT1-miR-155 signaling axis.

Myeloid Cell TRAF3 Promotes Metabolic Inflammation, Insulin Resistance, and Hepatic Steatosis in Obesity.

JMJD6 in tumor-associated macrophage regulates macrophage polarization and cancer progression via STAT3/IL-10 axis

Transcriptional factor EB regulates macrophage polarization in the tumor microenvironment

TRAF3-interacting JNK-activating Modulator Promotes Inflammation by Stimulating Translocation of Toll-like Receptor 4 to Lipid Rafts

Proinflammatory TLR Signalling is Regulated by a TRAF2-dependent Proteolysis Mechanism in Macrophages.

The N6-methyladenosine (M6a)-Forming Enzyme METTL3 Facilitates M1 Macrophage Polarization Through the Methylation of STAT1 Mrna

Targeting Crosstalk of STAT3 Between Tumor-Associated M2 Macrophages and Tregs in Colorectal Cancer.

The IL-33/ST2 Axis Affects Tumor Growth by Regulating Mitophagy in Macrophages and Reprogramming Their Polarization.

The NR_109/FUBP1/c-Myc axis regulates TAM polarization and remodels the tumor microenvironment to promote cancer development

PRMT2 silencing regulates macrophage polarization through activation of STAT1 or inhibition of STAT6